The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1047
February 26, 1999
View Complete Issue         Table of Contents 2019 
Rifapentine--A Long-Acting Rifamycin for Tuberculosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rifapentine--A Long-Acting Rifamycin for Tuberculosis
February 26, 1999 (Issue: 1047)
Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rifapentine--A Long-Acting Rifamycin for Tuberculosis
Article code: 1047c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.